Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,959.00
Bid: 1,952.00
Ask: 1,954.00
Change: 29.00 (1.50%)
Spread: 2.00 (0.102%)
Open: 1,947.00
High: 1,970.00
Low: 1,926.00
Prev. Close: 1,930.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broker tips: Johnston Press, Direct Line, Hikma Pharmaceuticals

Thu, 04th Aug 2016 11:01

(ShareCast News) - Johnston Press shares plunged on Thursday as Numis placed its rating and target price 'under review' after the company swung to a first half loss.For the 26 weeks to 2 July, the company posted a statutory pre-tax loss of £183.7m versus a £2.2m profit the year before, as it booked a £183.6m non-cash impairment reflecting a change of assumptions on its publishing titles and print assets.Advertising revenues were down 17.9% in the first quarter but improved marginally, with a 15% drop in the second quarter despite the impact of the run-up to and uncertainty following the UK's vote to leave the European Union in June.Chief executive Ashley Highfield said the market continues to be challenging and uncertainty surrounding the outcome of the Brexit negotiations has caused further softness in some segments of the advertising market, in June and July.Numis said the half year results came in below its estimates at every level."Our key issue at Johnston remains debt which has risen to £209m (from £179.4m) representing almost 4x our annualised EBITDA."This material debt pile, relative to cashflows, in combination with the declining and uncertain trading environment place a significant question mark on the equity value in the business."Numis said it expects to cut estimates "reasonably sharply" in both fiscal years 2016 and 2017. Direct Line Insurance Group's rating has been downgraded to 'hold' from 'buy' by Berenberg as the broker said "questions remain about earnings sustainability"."We believe there is some risk regarding the sustainability of Direct Line's earnings," Berenberg said in a note on Wednesday."High reserve releases, lower than forecast cost savings and a shrinking direct market all cast doubt on future earnings."Berenberg said older accident years have been incredibly profitable for Direct Line but these years are now contributing increasingly less releases.The broker said it does not expect to see the same developments in more recent accident years. Berenberg believes it will be difficult for management to offset falling reserve releases with the current accident year and operating improvements."As reserve releases decline, we expect earnings to be flat at best, thus we believe it will be challenging to grow the dividend from here," the broker said.Berenberg reiterated a target price of 406p.Direct Line on Tuesday posted its half year report for the six months to 30 June on Tuesday. Operating profit fell 5% to £316.9m, hurt by lower investment gains and the new Flood Re levy, but the group beat its own consensus estimates of £263m. Analysts at Citi downgraded their recommendation on shares of Hikma Pharmaceuticals in the wake of the company´s trading update which was issued after the close of trading in London on 3 August.Hikma flagged new drug approvals were arriving more slowly than expected and the phasing of litigation costs at US generics.On the basis of the above, the broker´s analysts lowered their recommendation on the shares from 'buy' to 'neutral' and set a target price of 2,600p.They also lowered estimates for the drugmaker´s core 2016 earnings before interest and taxes and earnings per share by 9.0% to $367m and $1.08, respectively - below the equivalent figures of $420m and $1.22 expected by the consensus.EPS estimates from 2017 onwards were cut by between 2% and 5% from 2017 onwards, with rates in foreign exchange markets expected to be an "incremental headwind".What was Citi´s view? "Developments at US Generics at best can be described as a 'short term hiccup'. At worse, sentiment concerns around the revenue/margin potential from the Roxane pipeline will increase, which is not helped by the lack of clarity on the pipeline given commercial sensitivities until 2017."If one were to cut his Roxane pipeline estimates by half, that would lead to EPS downgrades of between -15.0% and -20.0%, Citi said.Citi estimated the company´s net present value (NPV) at 2,900p, with a weighted average cost of capital of 8.0%, a terminal growth value (the rate at which free cash flows are expected to grow for eternity) of 2.0% and cable´s exchange rate at 1.32.
More News
10 Nov 2020 13:17

Tuesday broker round-up

(Sharecast News) - On the Beach: Citigroup downgrades to neutral with a target price of 370p.

Read more
10 Nov 2020 09:44

UK BROKER RATINGS SUMMARY: Investec Cuts Barclays; Goldman Raises Next

UK BROKER RATINGS SUMMARY: Investec Cuts Barclays; Goldman Raises Next

Read more
5 Nov 2020 10:44

TOP NEWS: Hikma Lifts Annual Guidance; Launches Generic Drug In US

TOP NEWS: Hikma Lifts Annual Guidance; Launches Generic Drug In US

Read more
5 Nov 2020 09:24

LONDON MARKET OPEN: Pound Keeps Lid On FTSE 100 As BoE Boosts Support

LONDON MARKET OPEN: Pound Keeps Lid On FTSE 100 As BoE Boosts Support

Read more
5 Nov 2020 09:15

Hikma raises FY guidance for generics unit following positive H1 momentum

(Sharecast News) - Pharmaceutical company Hikma said on Thursday that the group as a whole was "performing well" and had maintained the positive momentum seen in the first half, leading it to reiterate guidance for one unit and raise it on another.

Read more
4 Nov 2020 17:06

LONDON MARKET CLOSE: Strong End To Choppy Session On Tight US Poll

LONDON MARKET CLOSE: Strong End To Choppy Session On Tight US Poll

Read more
4 Nov 2020 12:12

LONDON MARKET MIDDAY: Stocks In Europe Shake Off US Poll Uncertainty

LONDON MARKET MIDDAY: Stocks In Europe Shake Off US Poll Uncertainty

Read more
4 Nov 2020 10:38

UK WINNERS & LOSERS SUMMARY: Pharmaceutical Firms Rally

UK WINNERS & LOSERS SUMMARY: Pharmaceutical Firms Rally

Read more
29 Oct 2020 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
20 Oct 2020 11:03

Hikma Pharmaceuticals Expands US Collaboration With Arecor

Hikma Pharmaceuticals Expands US Collaboration With Arecor

Read more
1 Oct 2020 09:42

UK BROKER RATINGS SUMMARY: Goldman Raises Coca-Cola HBC And Cuts DCC

UK BROKER RATINGS SUMMARY: Goldman Raises Coca-Cola HBC And Cuts DCC

Read more
22 Sep 2020 19:34

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

Read more
22 Sep 2020 17:04

LONDON MARKET CLOSE: Stocks Rebound Slightly As Covid-19 Fears Remain

LONDON MARKET CLOSE: Stocks Rebound Slightly As Covid-19 Fears Remain

Read more
22 Sep 2020 10:37

UK WINNERS & LOSERS SUMMARY: Beazley's Virus Claims Estimate Doubles

UK WINNERS & LOSERS SUMMARY: Beazley's Virus Claims Estimate Doubles

Read more
22 Sep 2020 08:48

Hikma Expects To Gain FDA Approval For Advair Diskus In Early 2021

Hikma Expects To Gain FDA Approval For Advair Diskus In Early 2021

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.